Drug Profile
Research programme: infectious diseases therapeutics - Achillion/Millenia Hope Biopharma
Latest Information Update: 05 Feb 2020
Price :
$50
*
At a glance
- Originator Achillion Pharmaceuticals; Millenia Hope Biopharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections; Viral infections
Most Recent Events
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals
- 21 Feb 2006 Avance Pharma has been acquired and merged into Millenia Hope Biopharma
- 06 Apr 2004 Phytobiotech is now called Avance Pharma